Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data
Rhea-AI Summary
Revelation Biosciences (NASDAQ:REVB) has issued a reminder for their upcoming webcast and conference call scheduled for September 10th at 8:30 am Eastern Time. The event will discuss top-line data from their PRIME Phase 1b clinical trial.
Participants can join via webcast or dial in using the toll-free number 888-506-0062 (US) or +1 973-528-0011 (International) with access code 289672. The company has made available both the original data announcement and the presentation materials on their website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, REVB gained 6.01%, reflecting a notable positive market reaction. Argus tracked a peak move of +20.6% during that session. Argus tracked a trough of -30.7% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $279K to the company's valuation, bringing the market cap to $5M at that time. Trading volume was exceptionally heavy at 93.9x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, wants to remind you of our September 10th webcast at 8:30 am Eastern Time, which can be accessed here or to call in, please dial 888-506-0062 (toll free in the US), +1 973-528-0011 (if International) and use the participant access code 289672. We look forward to reviewing the data with you tomorrow morning.
A copy of the original press release announcing data can be found here.
A copy of the presentation to be reviewed can be found here.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as prevention for acute kidney injury and the treatment of chronic kidney disease.
For more information on Revelation, please visit https://www.revbiosciences.com.
Company Contact
Mike Porter
Investor Relations
Porter LaVay & Rose Inc.
Email: mike@plrinvest.com
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
SOURCE: Revelation Biosciences, Inc.
View the original press release on ACCESS Newswire
FAQ
When is Revelation Biosciences (REVB) hosting its PRIME Phase 1b data webcast?
How can investors join Revelation Biosciences' PRIME Phase 1b data conference call?
What will be discussed in REVB's upcoming conference call?
Where can investors find materials for Revelation Biosciences' PRIME Phase 1b presentation?
